Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

摘要: In inflammatory dilated cardiomyopathy and myocarditis there is—apart from heart failure antiarrhythmic therapies—no alternative to an aetiologically driven specific treatment. Prerequisite are noninvasive invasive biomarkers including endomyocardial biopsy PCR on cardiotropic agents. This review deals with the different etiologies of genetic background, predisposition for inflammation. It analyses epidemiologic shift in pathogenetic agents last 20 years, role innate aquired immunity T- B-cell immune responses. The phases clinical faces summarized. Up-to-date information current treatment options starting therapy provided. Although inflammation can resolve spontaneously, directed causative aetiology is often required. For fulminant, acute chronic autoreactive immunosuppressive beneficial, while viral ivIg as successful interferon enteroviral adenoviral myocarditis. Parvo B19 HHV6 eradication virus still a problem by any these options. Finally, potential stem cell has be tested future trials. virus-negative, perimyocardial disease locoregional approach intrapericardial instillation high local doses triamcinolone acetate been shown highly efficient few systemic side-effects.